Physician profile
Simon M Ritchken
NPI 1255399341
$11,532.13
in general payments reported to CMS, 2019-2025
71 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $1,033 · 2021: $2,405 · 2022: $1,944 · 2023: $1,275 · 2024: $2,126 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,017.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,031.08 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Amgen INC. | $749.94 | 2019-2025 | Evenity, Prolia, Repatha |
| Nestle Healthcare Nutrition INC. | $722.42 | 2021-2023 | |
| Janssen Biotech, INC. | $708.86 | 2021-2024 | Stelara, Simponi, Simponi Aria |
| Lilly USA, LLC | $620.62 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $565.68 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $529.81 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $496.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $342.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $305.04 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.37 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $245.70 | 2019-2021 | |
| Beta Bionics, INC. | $240.46 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Intercept Pharmaceuticals, INC. | $214.33 | 2019-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $213.69 | 2024-2025 | Zenpep |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Ritchken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.